# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Jason Wittes maintains iRadimed (NASDAQ:IRMD) with a Buy and lowers the price target from $65 to $60.
"Looking ahead to the year's second half, we are confident in maintaining our strong financial performance. For the thi...
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.36 by 16....
IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) comp...
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.8...